Skip to main
VNRX
VNRX logo

Volitionrx Limited (VNRX) Stock Forecast & Price Target

Volitionrx Limited (VNRX) Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

VolitionRX Ltd is positioned for substantial topline growth due to potential upfront and milestone payments, along with future recurring royalties stemming from its innovative blood tests developed through the Nucleosomics platform. The recent co-marketing agreement is expected to enhance the customer base for its Nu.Q Discover services, thereby increasing market penetration and revenue opportunities. Additionally, the strategic partnership with the Immunoassay Technology Center of Werfen, including exclusive commercial option rights, further solidifies Volition's foothold in the diagnostics market, potentially leading to significant financial gains.

Bears say

VolitionRX faces significant operational risks that could adversely impact its financial performance, including potential failures in the clinical development of diagnostic products and challenges in securing necessary licensing agreements. Additionally, the company's struggle to achieve market traction with its diagnostic offerings, alongside the risks of dilution and going concern issues, raise further concerns about its financial stability. These factors collectively contribute to a negative outlook for VolitionRX's stock as the company navigates a competitive and uncertain market environment.

Volitionrx Limited (VNRX) has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Volitionrx Limited and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Volitionrx Limited (VNRX) Forecast

Analysts have given Volitionrx Limited (VNRX) a Strong Buy based on their latest research and market trends.

According to 4 analysts, Volitionrx Limited (VNRX) has a Strong Buy consensus rating as of Oct 30, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $3.88, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $3.88, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Volitionrx Limited (VNRX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.